This preprint is under consideration at BMC Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Shilong Fu
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7416-3070
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Cervical cancer (CC) is the primary cause of death in women. This study sought to investigate the therapeutic targets of CC.
Methods: We downloaded four gene expression profiles from GEO. The RRA method was used to integrate and screen DEGs between CC and normal samples. Functional analysis was performed by clusterprofiler. We built PPI network by STRING and selected hub modules via MCODE. CMap was used to find molecules with therapeutic potential for CC. We also validated hub genes in GEO datasets, GEPIA, immunohistochemistry. Cox regression analysis, TCGA methylation analysis and ONCOMINE were carried out. ROC curve analysis and GSEA were also done to dig out the significance of hub genes.
Results: Functional analysis revealed that DEGs were significantly enriched in binding, cell proliferation, transcriptional activity and cell cycle regulation. PPI network screened 30 prominent proteins, with CDK1 having the strongest association with CC. Cmap showed that apigenin, thioguanine and trichostatin A might be used to treat CC. Eight genes were screened out through GEPIA. Of them, only PTGDS and SNX10 have not been reported in CC related articles. The validation in GEO showed that PTGDS showed low expression in tumor tissues while SNX10 showed high expression in tumor tissues. Their expression profiles were consistent with the results in immunohistochemistry. They can distinguish CC and normal tissue and have good diagnostic efficiency. GSEA showed that the two genes were associated with the chemokine signaling pathway. TCGA methylation analysis showed that patients with low-expressed and hyper-methylated PTGDS had a bad prognosis than the patients with high-expressed and hypo-methylated PTGDS. Cox regression analysis showed that SNX10 and PTGDS were independent prognostic indicators for OS among CC patients.
Conclusions: In conclusion, PTGDS and SNX10 showed abnormal expression and methylation in CC. Both genes could be used to develop new target treatments for CC.
Keywords
Cervical squamous cell carcinoma, methylation，prognosis，risk model，SNX10, PTGDS
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
This is a list of supplementary files associated with this preprint. Click to download.
- FigureSupp.docx
- SupplementaryFigure12.tif
- SupplementaryFigure11.tiff
- SupplementaryFigure10.tif
- SupplementaryFigure9.tif
- SupplementaryFigure8.tif
- SupplementaryFigure7.tif
- SupplementaryFigure6.tif
- SupplementaryFigure5.tif
- SupplementaryFigure4.tif
- SupplementaryFigure3.tif
- SupplementaryFigure2.tif
- SupplementaryFigure1.tif
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
The most recent version of this article is available here.
No community comments so far
Submission checks complete
On 30 Dec, 2020
Editorial decision: Minor revision
On 20 Dec, 2020
No comments provided
Editorial decision: Minor revision
On 23 Nov, 2020
Editor assigned
On 18 Nov, 2020
Submission checks complete
On 18 Nov, 2020
Editor invited
On 18 Nov, 2020
No comments provided
Editorial decision: Minor revision
On 09 Nov, 2020
Review #2 received
Received 07 Nov, 2020
Review #1 received
Received 24 Oct, 2020
Reviewer #2 agreed
On 14 Oct, 2020
Reviewers invited
Invitations sent on 13 Oct, 2020
Reviewer #1 agreed
On 13 Oct, 2020
Editor assigned
On 28 Sep, 2020
Submission checks complete
On 27 Sep, 2020
Editor invited
On 27 Sep, 2020
Version 1
Posted 04 Aug, 2020
No comments provided
Editorial decision: Major revision
On 20 Aug, 2020
Review #2 received
Received 18 Aug, 2020
Review #1 received
Received 16 Aug, 2020
Reviewer #3 agreed
On 11 Aug, 2020
Reviewer #2 agreed
On 09 Aug, 2020
Reviewers invited
Invitations sent on 08 Aug, 2020
Reviewer #1 agreed
On 08 Aug, 2020
First submitted
On 28 Jul, 2020
Editor assigned
On 28 Jul, 2020
Submission checks complete
On 27 Jul, 2020
Editor invited
On 27 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This preprint is under consideration at BMC Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Shilong Fu
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7416-3070
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
The most recent version of this article is available here.
No community comments so far
Submission checks complete
On 30 Dec, 2020
Editorial decision: Minor revision
On 20 Dec, 2020
No comments provided
Editorial decision: Minor revision
On 23 Nov, 2020
Editor assigned
On 18 Nov, 2020
Submission checks complete
On 18 Nov, 2020
Editor invited
On 18 Nov, 2020
No comments provided
Editorial decision: Minor revision
On 09 Nov, 2020
Review #2 received
Received 07 Nov, 2020
Review #1 received
Received 24 Oct, 2020
Reviewer #2 agreed
On 14 Oct, 2020
Reviewers invited
Invitations sent on 13 Oct, 2020
Reviewer #1 agreed
On 13 Oct, 2020
Editor assigned
On 28 Sep, 2020
Submission checks complete
On 27 Sep, 2020
Editor invited
On 27 Sep, 2020
Version 1
Posted 04 Aug, 2020
No comments provided
Editorial decision: Major revision
On 20 Aug, 2020
Review #2 received
Received 18 Aug, 2020
Review #1 received
Received 16 Aug, 2020
Reviewer #3 agreed
On 11 Aug, 2020
Reviewer #2 agreed
On 09 Aug, 2020
Reviewers invited
Invitations sent on 08 Aug, 2020
Reviewer #1 agreed
On 08 Aug, 2020
First submitted
On 28 Jul, 2020
Editor assigned
On 28 Jul, 2020
Submission checks complete
On 27 Jul, 2020
Editor invited
On 27 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The most recent version of this article is available here.
Background: Cervical cancer (CC) is the primary cause of death in women. This study sought to investigate the therapeutic targets of CC.
Methods: We downloaded four gene expression profiles from GEO. The RRA method was used to integrate and screen DEGs between CC and normal samples. Functional analysis was performed by clusterprofiler. We built PPI network by STRING and selected hub modules via MCODE. CMap was used to find molecules with therapeutic potential for CC. We also validated hub genes in GEO datasets, GEPIA, immunohistochemistry. Cox regression analysis, TCGA methylation analysis and ONCOMINE were carried out. ROC curve analysis and GSEA were also done to dig out the significance of hub genes.
Results: Functional analysis revealed that DEGs were significantly enriched in binding, cell proliferation, transcriptional activity and cell cycle regulation. PPI network screened 30 prominent proteins, with CDK1 having the strongest association with CC. Cmap showed that apigenin, thioguanine and trichostatin A might be used to treat CC. Eight genes were screened out through GEPIA. Of them, only PTGDS and SNX10 have not been reported in CC related articles. The validation in GEO showed that PTGDS showed low expression in tumor tissues while SNX10 showed high expression in tumor tissues. Their expression profiles were consistent with the results in immunohistochemistry. They can distinguish CC and normal tissue and have good diagnostic efficiency. GSEA showed that the two genes were associated with the chemokine signaling pathway. TCGA methylation analysis showed that patients with low-expressed and hyper-methylated PTGDS had a bad prognosis than the patients with high-expressed and hypo-methylated PTGDS. Cox regression analysis showed that SNX10 and PTGDS were independent prognostic indicators for OS among CC patients.
Conclusions: In conclusion, PTGDS and SNX10 showed abnormal expression and methylation in CC. Both genes could be used to develop new target treatments for CC.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
This is a list of supplementary files associated with this preprint. Click to download.
- FigureSupp.docx
- SupplementaryFigure12.tif
- SupplementaryFigure11.tiff
- SupplementaryFigure10.tif
- SupplementaryFigure9.tif
- SupplementaryFigure8.tif
- SupplementaryFigure7.tif
- SupplementaryFigure6.tif
- SupplementaryFigure5.tif
- SupplementaryFigure4.tif
- SupplementaryFigure3.tif
- SupplementaryFigure2.tif
- SupplementaryFigure1.tif
Loading...